Noveris Health Sciences Announces Results Of 2026 Annual General And Special Meeting
| | Votes | Percentage |
| For | 21,691,077 | 99.97% |
| Against | 6,516 | 0.03% |
Election of Directors
Shareholders elected Jason Birmingham, Michael Callas and Peter Field as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed.
| Nominee | Votes For | % For | Votes Withheld | % Withheld |
| Jason Birmingham | 21,693,551 | 99.98% | 4,042 | 0.02% |
| Michael Callas | 21,692,406 | 99.98% | 5,187 | 0.02% |
| Peter Field | 21,694,050 | 99.98% | 3,543 | 0.02% |
Appointment of Auditor
Shareholders approved the appointment of HDCPA Professional Corporation as auditor of the Company for the ensuing year and authorized the directors to fix the auditor's remuneration.
| | Votes | Percentage |
| For | 21,693,250 | 99.98% |
| Withheld | 4,343 | 0.02% |
Omnibus Long-Term Incentive Plan
Shareholders approved the Company's Amended and Restated Omnibus Long-Term Incentive Plan.
| | Votes | Percentage |
| For | 21,674,601 | 99.89% |
| Against | 22,992 | 0.11% |
Amendment to Articles
Shareholders approved the special resolution authorizing an amendment to the Company's Articles to change the quorum requirements.
| | Votes | Percentage |
| For | 21,683,976 | 99.94% |
| Against | 13,617 | 0.06% |
The Company thanks its shareholders for their participation in the Meeting and their continued support.
About Noveris Health Sciences Inc.
Noveris Health Sciences Inc. is a Canadian life sciences company focused on opportunities in mental health and therapeutic innovation. Additional information concerning the Company is available under its profile on SEDAR+ at and at .
On behalf of the Board of Directors
NOVERIS HEALTH SCIENCES INC.
Jason Birmingham, Chief Executive Officer
For Further Information
Tel: +1 778-900-NVRS (6877)
Email: ...th
Web:
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit
Source: Noveris Health Sciences Inc.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.

Comments
No comment